Insulin receptor (IR) insufficiency in b-cells leads to impaired insulin secretion and reduced b-cell hyperplasia in response to hyperglycemia. Selective IR deficiency in b-cells in later embryological development may lead to compensatory b-cell hyperplasia. Although these findings suggest insulin signaling on the b-cell is important for b-cell function, they are confounded by loss of signaling by the insulinlike growth factors through the IR. To determine whether insulin itself is necessary for b-cell development and maturation, we performed a characterization of pancreatic islets in mice with deletions of both nonallelic insulin genes (Ins1
2/2

Ins2
2/2
). We immunostained neonatal Ins1 D iabetes affects .400 million people worldwide (1) and imposes high financial, disability, and mortality costs for health care systems and patients around the world (2) . Regardless the type of diabetes (type 1, type 2, gestational, or rare forms), all patients with diabetes develop an eventual insufficiency of the hormone insulin (3) . In humans, b-cells containing insulin first begin to appear in the pancreas at week 7 of development, and insulin acts as a powerful anabolic signaling molecule starting in the 26th week of gestation (4) . Uptake of glucose into cells is a fundamental biological process that is almost always dependent on the actions of insulin (5) . Without insulin, subjects face elevated glucose and glucagon levels, increased stress hormones and ketogenesis, and eventual death from severe ketoacidosis (6) . However, insulin may also play other roles independent of directly lowering blood glucose, including serving as an important signaling molecule on the b-cell itself.
Mice with targeted disruption of insulin receptors (IRs) on b-cells have impaired glucose-stimulated insulin secretion and glucose intolerance (7) . IRs on b-cells are necessary for b-cell hyperplasia in response to insulin resistance (8) . These studies (7, 8) used a transgenic mouse model with the rat insulin promoter expressing Cre, with a floxed insulin receptor gene (Insr). Cre is expressed after E9.5 when insulin first appears in the mouse pancreas (9) and recombines to delete the IR from 80% (10) of b-cells and regions of the brain (11) . Delayed and incomplete recombination allows some insulin signaling in b-cells beyond E9.5, and impaired insulin action in the brain can promote obesity and insulin resistance (12) . Therefore, these findings do not conclusively demonstrate that a loss of insulin signaling in b-cells is responsible for the observed phenotype. Recently, Trinder et al. (13) addressed the caveat of central recombination by using mice with an inducible Cre transgene driven by a mouse insulin I promoter to generate IR deficiency selectively in b-cells after E13. MIPCreERT mice had reduced b-cell mass at birth, but as in previous studies using the RIP-Cre line, these mice retained alternative insulin signaling pathways and attenuated insulinlike growth factor (IGF) signaling in b-cells through the IR, making it challenging to conclude that a loss of insulin action in b-cells was entirely responsible for the phenotype.
Alongside incomplete b-cell recombination, delayed loss of IRs until later in development, and the presence of a human growth hormone minigene in the MIPCreERT transgene (14, 15) , there are other important factors to consider when attempting to study a loss of insulin signaling by using a model with deletion of the IR. First, insulin may signal with low affinity through IGF receptors I and II (16, 17) , and it is possible that there are other insulin signaling pathways not yet appreciated. Hyperinsulinemia in b-cell IR-deficient mice may increase the likelihood of insulin signaling via the IGF receptors (7) . Second, IGF-I and IGF-II bind the IR and play essential roles in embryological mammalian development (18) . In fact, binding of IGF-II to the IR appears to be the most important signal through the IR during development (19) . Thus, deleting the IR may not completely block all actions of insulin and impairs the IR-mediated actions of the IGF hormones. We posit that the only model capable of defining the role of insulin in b-cell development and maturation is a model with a loss of the insulin gene itself. mice and mice maintained into adulthood by insulin replacement therapy. We found that alongside a complete loss of insulin production, b-cells of Ins1 2/2 Ins2 2/2 mice lacked many markers of mature b-cells and were present in islets of abnormal size and endocrine hormone composition. Additionally, insulindeficient b-cells expressed markers of dedifferentiation and dysfunction, suggesting that insulin is a necessary signal for completely maturing b-cells or maintaining their maturity. Short-term replacement of insulin in the insulin knockout mice via exogenous injection facilitated a partial normalization of the b-cell phenotype but was associated with islet fibrosis. Long-term replacement of insulin by isogenic islet transplantation was sufficient for the maturation of insulin-deficient b-cells. This model provides direct evidence that insulin itself is needed for normal b-cell development and the maintenance of normal b-cell function. 0 -CAG GAA GCA GAA TTC CAG ATA, and probe 5 0 -GGG CTG CAG GAA TTC GAT ATC AAG C). Briefly, animals received twicedaily subcutaneous injections of~0.1 U insulin glargine diluted to 5 U/mL in F-10 media (Lantus ® ; Sigma-Aldrich, St. Louis, MO). Because regular blood glucose sampling is not possible with young pups, health of the animals was tracked by body weight and glycosuria, and when animals failed to gain weight or lost weight, insulin dosing was halved or skipped. When animals presented with severe glycosuria, we increased the insulin dose. As pups grew, we began regular blood sampling to better refine insulin doses. Therapy continued for up to 291 days. Mortality by this method was initially extremely high (.90%) but decreased with experience to ,50% for animals analyzed in this study. Some animals received islet transplants into the anterior chamber of the eye at 14 days of age. In all experiments, we present findings from a mix of male and female animals.
Materials and Methods
Animal breeding and insulin therapy
Islet isolation and transplantation
Newborn Ins1
2/2 Ins2 2/2 or Ins1 +/+ Ins2 +/+ mice were euthanized by decapitation upon first discovery (P0 to P1), and pancreatic islets were isolated by collagenase digestion (24) . After euthanasia, we performed a rapid dissection and exposed the pancreatic duct. Approximately 1 mL of collagenase solution (1000 U/mL type XI collagenase; Sigma-Aldrich; diluted in Hanks buffer without CaCl 2 ) was injected into the pancreatic duct. The pancreas was then excised and digested for 6 to 8 minutes at 37°C in 3 mL of collagenase. Islets were then handpicked three times in medium (Hams F10, 7.5% fetal bovine serum, and penicillin/streptomycin; Sigma-Aldrich) to increase purity to .90%. Islets were washed in phosphatebuffered saline (PBS) and immediately lysed by forceful suction into a 20-gauge needle 20 to 30 times in 50 mL of QIAzol Lysis Reagent (Qiagen, Toronto, ON, Canada) before storage at 280°C.
Islet isolation from donor adult C57Bl/6 mice (used for transplantation) was completed in the same fashion, with slight changes (incubation in collagenase for 12 to 15 minutes at 37°C). After handpicking, islets were cultured overnight, visually inspected for purity, and washed in sterile PBS before transplantation. After 2 weeks of insulin therapy with insulin glargine (Lantus ® ), Ins1 2/2 Ins2 2/2 animals received an islet transplant into the anterior chamber of the eye (~100 to 150 islets) as previously described (25) . This procedure is technically feasible at 2 weeks of age and provides reversal of diabetes within 24 hours. Animals were anesthetized by inhaled isoflurane (5%) and maintained at 1% to 3%. The cornea was punctured with a 27-gauge needle to gain access to the anterior chamber of the eye. Islets were loaded into a micropipette (MXL3-BP-IND-200; Origio MidAtlantic Devices, Mt. Laurel, NJ), the micropipette was passed through the opening in the cornea, and islets were deposited with a micromanipulator. After removal of the micropipette, animals received Isoptears (Alcon Canada, Mississauga, ON, Canada) with 0.3% wt/vol gentamycin to prevent infection.
Immunohistochemistry and immunohistofluorescence
Pancreata were dissected out of mice, washed in PBS, and fixed in 4% paraformaldehyde overnight before being transferred to 70% ethanol for long-term storage before paraffin embedding and sectioning (5 mm thickness; Wax-It Histology Services, Vancouver, Canada). Hematoxylin and eosin and Masson's trichome staining was performed by standard protocol, and slides were scanned with the ScanScope CS system (Aperio, Vista, CA). Immunofluorescent staining was performed as previously described (26) .
Briefly, sections were deparaffinized in xylene (15 minutes) and rehydrated in graded ethanol (100% 2 3 5 minutes, 95% 5 minutes, 70% 5 minutes, and PBS 10 minutes) before heatinduced epitope retrieval in an EZ Retriever microwave oven (BioGenes, Fremont, CA) for 15 minutes at 95°C in 10 mM citrate buffer (0.5% Tween 20, pH 6.0; Thermo Fisher Scientific, Waltham, MA). Samples were blocked in DAKO Protein Block, Serum Free (Dako, Burlington, Canada) and incubated overnight in primary antibody diluted in Dako Antibody Diluent (Dako). The next day, slides were washed and incubated in secondary antibody for 1 hour at room temperature before mounting and counterstaining with nuclear stain 4 0 ,6-diamidino-2-phenylindole (DAPI) and VECTASHIELD ® Hard Set Mounting Medium with DAPI (Vector Laboratories, Burlingame, CA). All images were captured and analyzed with an ImageXpress ® Micro XLS System, controlled by MetaXpress ® High-Content Image Acquisition & Analysis Software (Molecular Devices Corporation, Sunnyvale, CA) with a scientific CMOS camera, a Nikon 203 Plan Apo objective (NA = 0.75, 1-6300-0196; Nikon, Tokyo, Japan), and DAPI (DAPI-5060B), FITC (FITC-3540B), Cy3 (Cy3-4040B), Texas Red (TXRED-4040B), and Cy5 (Cy5-4040A) filter cubes. We performed quantification of histological images in the same software (MetaXpress ® ). We used islet amyloid polypeptide (IAPP), insulin, or bGAL to label b-cells, glucagon (GCG) to label a-cells, somatostatin (SST) to label d-cells, and pancreatic polypeptide (PP) to label pancreatic polypeptide cells. Of note, although d-cells are known to express some IAPP (27) , given the smaller number of d-cells, lower expression level, and limited colocalization of SST and IAPP (data not shown), we use bright IAPP immunoreactivity as a marker of b-cells. We immunostained for synaptophysin (SYN) to identify islet cells and quantify islet size and number. We calculated endocrine cell area of each cell type by quantifying immunoreactive surface area relative to total pancreas surface area and calculated the average of three immunostained sections 50 to 100 mM apart for each animal. We calculated the proportion of b-cells with positive immunoreactivity for proteins of interest or total immunoreactive area of proteins of interest by thresholding images and using a multiwavelength cell scoring journal in MetaXpress ® , and we used image analysis to find the mean fluorescent intensity of positive signal in relevant cell compartments.
RNA isolation and quantitative reverse transcription polymerase chain reaction
After islet isolation, lysis, and storage in Qiazol Lysis Reagent (Qiagen), we performed acid guanidinium thiocyanatephenol-chloroform extraction by standard methods (28) . To ensure sufficient quantity of mRNA for downstream applications, we pooled lysed islets from three to five mice in each group of Ins1 2/2 Ins2 2/2 , Ins1 2/2 Ins2 +/2 , or Ins1 +/+ Ins2 +/+ animals, for a total of 25 to 35 islets per sample. We generated complementary DNA from isolated islet RNA by using a RevertAid H Minus First Strand cDNA synthesis kit (Thermo Fisher Scientific) according to the manufacturer's protocol. We quantified mRNA levels of target genes via the 2 2DDCT method (glyceraldehyde 3-phosphate dehydrogenase used as housekeeping gene) by using the SsoFast EvaGreen Supermix (Bio-Rad, Mississauga, Canada) kit according to the manufacturer's protocol (for primer details see Supplemental Table 1 ).
Statistics
Data were subject to the Shapiro-Wilk normality test, and when all groups passed the test for normality we analyzed them by Student t test, one-way analysis of variance with Tukey test for multiple comparisons, or two-way analysis of variance with Bonferroni post hoc testing. When one or more groups failed the test for normality, we used the nonparametric Mann-Whitney U test or Kruskal-Wallis test with the Dunn multiple comparisons test. Statistical analysis was performed in GraphPad Prism 7.01 (La Jolla, CA) with significance set at P , 0.05. 
Results
Ins1
Insulin-deficient islets are enlarged and have an abnormal endocrine cell distribution
We characterized the endocrine cell distribution of neonatal islets to determine whether a lack of insulin causes a shift in endocrine cell proportions. Ins1 (30)]. We immunostained for ghrelin and found extremely rare cells, as expected, in both controls and insulin-deficient islets (data not shown). Insulin-deficient islets were fewer in number ( Fig. 2D ) but more than three times as large as islets in pancreata of Ins1 +/+ Ins2 +/+ control mice (Fig. 2E) . We immunostained for the proliferating cell nuclear antigen (PCNA) as a marker of replicating cells and observed a pronounced increase in proportion of IAPP+PCNA+/IAPP+ cells in Ins1 2/2 Ins2 2/2 mice compared with controls (Fig. 2F ).
Insulin-deficient b-cells lack many markers of mature b-cells
We examined the maturity of the insulin-deficient b-cells by immunostaining for select markers of mature bcells. Interestingly, for some proteins the immunoreactivity appeared to coincide with the feeding and glycemia status of the animals. IAPP+ cells of hypoglycemic insulin-deficient mice had normal levels of PDX1 (Fig. 3A) (Fig. 4A) . In hypoglycemic insulin-deficient neonates, immunoreactivity of sulfonylurea receptor 1 (SUR1) (Fig. 4B) , prohormone convertase 1/3 (PC1/3) (Fig. 4C) , and prohormone convertase 2 (PC2) (Fig. 4D) We examined transcript levels by qPCR and found reduced expression of Ins, Gcg, Sst, and Ppy, as well as Pdx1, Nkx6.1, Nkx2.2, Pax6, Sur1, and Pcsk2 in isolated islets from hypoglycemic Ins1 2/2 Ins2 2/2 pups compared with Ins1 +/+ Ins2 +/+ controls, and mRNA expression levels of Slc2a2, Gck, and Pcsk1 were similar to levels in islets from control mice (Fig. 4E) . We found comparable expression of Amy in samples, indicating that the differences observed in expression levels of other target genes were unlikely to be a result of variable pancreatic exocrine contamination of samples.
Insulin-deficient b-cells express progenitor markers
We next determined whether insulin-deficient b-cells of Ins1 Fig. 5A-5C ). This finding contrasts with that of neurogenin-3 (NGN3), which was present in the perinuclear area of SYN+ islets cells in Ins1 +/+ Ins2 +/+ controls but absent from Ins1 2/2 Ins2 2/2 islet cells (Fig. 5D) . We repeated NGN3 immunostaining by using two commercially available antibodies (R&D Systems, catalog #AF3444; and Thermo Fisher Scientific, catalog #PA5-11893) and found similar patterns of immunoreactivity (Supplemental Fig. 3 ). The proportion of b-cells that were L-MYC+ or ALDH1A3+ was significantly higher in Ins1 2/2 Ins2 2/2 mice relative to controls.
A3 (ALDH1A3;
b-cells had higher intensity for immunoreactive NANOG and L-MYC compared with control samples. We attempted to quantify the corresponding gene levels by qPCR but could detect sufficient transcript only of Aldh1a3, which was about eight times higher in islets of in Ins1 2/2 Ins2 2/2 mice than in controls (Fig. 5C ).
Insulin replacement by injection leads to islet fibrosis and expanded islet cell area To determine whether restoration of insulin signaling by exogenous insulin therapy was sufficient for completed b-cell maturation, we treated insulin-deficient animals with insulin injections for 2 months. Insulininjected Ins 2/2 Ins2 2/2 mice gained weight but at a slower rate than control animals (Supplemental Fig. 4A ).
After insulin therapy by injection or isogenic islet transplantation from Ins1 +/+ Ins2 +/+ donors, animals retained clusters of IAPP+ cells, but the majority of IAPP+ cells were bGAL2 (Supplemental Fig. 4B-4D Fig. 4E ).
After 2 months of insulin therapy by injections, we found islet cell hyperplasia and obvious islet fibrosis by trichrome staining in insulin-deficient islets (Fig. 6A) . Although a smaller proportion of endocrine cells were IAPP+ b-cells (Fig. 6B) , we observed an expansion of all endocrine cell types relative to total pancreatic area in Ins1 2/2 Ins2 2/2 mice compared with Ins1 +/+ Ins2 +/+ controls (Fig. 6C) . Furthermore, Ins1 2/2 Ins2 2/2 islets trended to being larger (Fig. 66E) , and there was a trend toward a higher proportion of IAPP+PCNA+/IAPP+ islet cells compared with controls (Fig. 6F) . b-cells (Fig. 7B) . Furthermore, Ins1 2/2 Ins2 2/2 islet cells were deficient in PAX6, MAFA, and GLUT2 compared with control islets (Fig. 7C-7E ). There was cytoplasmic NANOG immunoreactivity in Ins1 2/2 Ins2 2/2 IAPP+ cells but no L-MYC+ cells (Fig. 77G) . Rare ALDH1A3+ cells were observed (Fig. 7H) , and pericytoplasmic immunoreactivity for NGN3 was frequent in Ins1 2/2 Ins2 2/2 IAPP+ b-cells and neighboring cells within the islet (Fig. 7I) , similar to Ins1 (Fig. 5D) .
Insulin replacement by injection facilitates partial maturation of Ins1
Insulin replacement by islet transplantation facilitates expansion and completed maturation of Ins1 2/2 Ins2 2/2 b-cells We next determined whether restoration of insulin signaling by isogenic islet transplantation into the anterior chamber of the eye was sufficient for completed b-cell maturation. We attempted to have a side-by-side comparison of the endocrine pancreas of animals treated for~1 year by insulin injections alone or islet transplantation into the anterior chamber of the eye at 2 weeks of age (Fig. 8) . Because of the major technical challenges in keeping Ins1
Ins2
2/2 animals alive with insulin injections for such a prolonged time, we were able to collect samples from only one mouse at 291 days of age. The mouse treated by injections had extreme islet fibrosis (Fig. 8A) , with a nearly complete loss of IAPP+ cells, and islets were .50% GCG+ (Supplemental Fig. 5A ). Compared with Ins1 +/+ Ins2 +/+ controls, mice treated with islet transplantation (n 5 4) had grossly normal-appearing islets without signs of fibrosis ( Fig. 8A ) and did not have significantly altered islet hormone proportions (Fig. 8B) , but there was a slightly expanded a-cell area (Fig. 8C ) and enlarged islets (Fig. 8E) . Unlike those of mice treated with insulin injections for 2 months (Fig. 7) , pancreatic b-cells of Ins1 2/2 Ins2 2/2 mice with healthy islets transplanted had normal immunoreactivity for PAX6, MAFA, and GLUT2 (Supplemental Fig. 5B ), but we detected the abnormal presence of NANOG+ cells (Supplemental Fig. 6 ). NGN3 immunoreactivity was not detected in pancreata of Ins1 2/2 Ins2 2/2 mice with transplanted islets, similar to adult Ins1 +/+ Ins2 +/+ controls (Supplemental Fig. 6 ).
Discussion
Mice lacking IRs on b-cells have impaired glucosestimulated insulin secretion (7), and b-cell mass expands during development (13) . IR-deficient b-cells are unable to sufficiently expand in response to hepatic insulin resistance, resulting in adult-onset diabetes (8) . In the current study, we characterized pancreata in neonatal Ins1 2/2 Ins2 2/2 mice and Ins1 2/2 Ins2 2/2 mice kept alive into adulthood by using insulin therapy. By using the insulin knockout mouse model as an alternative to IRdeficient mice, we provide evidence that insulin itself is necessary for b-cell maturation and insulin deficiency alters islet development. However, we cannot rule out the possibility that IGF signaling though the IR is altered by changes to expression of the IR or insulinlike growth factor 1 receptor (IGF1R) and downstream signaling components. Additionally, it is possible that other defects secondary to the genetic deletion of insulin contribute to the observed b-cell phenotype. Independent of these caveats, we posit that the insulin-deficient mouse model provides the best evidence available that signaling by insulin itself is necessary for b-cell maturation. Certainly, the Ins1 2/2 Ins2 2/2 mouse model does not have any insulin signaling via an IR-independent pathway, and unlike in the IR-deficient model, there is no direct and complete loss of IGF signaling through the IR. At birth, insulin-deficient islets were enlarged with an expanded IAPP+ area. These findings are consistent with observations of expanded b-cell mass and increased b-cell replication in the MIP-CreER/IR flox/flox (tamoxifen at E13) model (13) and reduce the likelihood that those findings were attributable to the presence of the growth hormone minigene within the transgene (32, 33) . We also observed a lack of mature b-cell factors PDX1, NKX6.1, MAFA, and membranous GLUT2 in insulin-deficient b-cells. These findings contrast with normal expression 
Ins2
2/2 (middle panels; n = 1, 9 months of age), and islet transplantation-treated Ins1 Because the primary deficit of Ins1 2/2 Ins2 2/2 mice is a loss of insulin, it is surprising that replacing insulin by injections alone or islet transplantation resulted in dramatically divergent outcomes for the endogenous b-cells. We proposed three variables that could contribute to the differences in b-cell phenotype between Ins1 2/2 Ins2 2/2 mice treated with islet transplantation and those treated with insulin injection: glycemic control was superior in mice treated with islet transplantation relative to those treated with insulin injections, native mouse insulin produced by transplanted islets may signal in b-cells with higher bioactivity than recombinant insulin (51, 52), or insulin-deficient islets may fail to produce other essential factors that are replaced by transplanted islets. Although we are unable to conclusively discern which, if any, of these variables contribute to the differences in b-cell phenotype, the striking resemblance in fibrotic islet phenotype between injection-treated Ins1 (53) suggests that differences in glycemia are at least partially responsible. Hyperglycemia leading to glucotoxicity has also been shown to cause reduced expression of Pdx1, Mafa, and Slc2a2 (36), and reprogramming of exocrine cells to insulin-producing cells was more complete and abundant from a viral therapy (expressing NGN3/PDX1/MAFA) when mice were treated with islet transplantation for good control of their toxin-induced diabetes compared with crude treatment with insulin pellets (54) . Similarly, in models of neonatal diabetes (expression of an activating ATP-sensitive potassium channel), animals treated with islet transplantation did not develop islet fibrosis and retained glucose-stimulated insulin secretion, unlike the untreated hyperglycemic group (55) . These findings also suggest that the crude glycemic regulation of insulin injections (or pellets) compared with the ideally regulated glycemia of mice treated with islet transplantation is probably an important contributor to the differences in b-cell phenotype. Transplanted islets also secrete additional peptides beyond insulin, including C-peptide, a byproduct of proinsulin processing that may contribute to preservation of islet health (56) . Finally, in this study the mice treated by islet transplantation were kept alive for~1 year, whereas injection-treated mice were kept alive for 2 months, with the exception of a single mouse that was kept alive by injections for nearly 1 year. and Ins1 2/2 Ins2 +/2 animals. Because expression of insulin is arguably the most important aspect of the pancreatic b-cell identity, loss of bGAL does not align with a mature b-cell identity. However, it is important to consider the model organism because age-dependent loss of bGAL in insulin-treated Ins1 2/2 Ins2 2/2 mice is consistent with reduced lacZ expression when knocked into the globin genes in mice (65) . The distinct expression pattern of bGAL compared with insulin in the insulin knockout/lacZ knockin model may be a caveat of the mouse model because there can be selective CpG methylation to silence a foreign open reading frame such as the lacZ gene (66) . Nevertheless, it may be worthwhile to further explore the possibility of differential regulation of the mouse insulin alleles. There have been many reported human cases of diabetes caused by mutations in the insulin gene. Most of these patients have a heterozygous dominant negative disease caused by misfolding of the mutated insulin, but there has been a report of patients with homozygous deletion of INS (68). Although we found no published histology of the pancreas from such patients, a patient with an intronic mutation causing altered splicing of INS had undetectable C-peptide but readily detectable IAPP, suggesting that the patient had insulin-deficient b-cells in the pancreas (69 histological examination (70) . Patients with mutations in the ATP-sensitive potassium channel are less likely to become insulin independent with sulfonylurea therapy the longer the patient has been insulin dependent (71) . Potentially there is a major change in b-cell maturity after transfer of therapy, but prolonged insulin replacement by injection causes progressive loss of b-cell mass, thus hindering the ability of sulfonylurea therapy to induce diabetic remission. This hypothesis aligns with our findings that although a lack of insulin during development initially results in an expanded b-cell mass, insulin replacement by injection is not sufficient to maintain b-cell mass. Like mouse b-cells, adult human b-cells also contain much of the necessary machinery for insulin signaling, including IRs and insulin receptor substrate (IRS)-1 and IRS-2 (72) . Functionally, inhibition of IR by short hairpin RNA impaired glucose-stimulated insulin secretion (72) , and human islets with an IRS-1 polymorphism have impaired glucose-stimulated insulin secretion, elevated proinsulin secretion, and reduced insulin content (73) . Furthermore, there is evidence of reduced insulin signaling in b-cells of patients with type 2 diabetes: IRS-1, IRS-2, Tyr612 IRS-1, and Tyr612 IRS-2 expression are reduced in islets from patients with type 2 diabetes compared with islets from nondiabetic donors (74) . Taken together, these findings lead us to propose that though usually attributed to reduced glucolipotoxicity (75) , diabetic remission after intensive insulin therapy in patients with type 2 diabetes (76) may be attributed partially to augmented b-cell insulin signaling from increased circulating insulin. 
